PL1873166T3 - Ulepszone dimery sgp 130Fc - Google Patents

Ulepszone dimery sgp 130Fc

Info

Publication number
PL1873166T3
PL1873166T3 PL06013668T PL06013668T PL1873166T3 PL 1873166 T3 PL1873166 T3 PL 1873166T3 PL 06013668 T PL06013668 T PL 06013668T PL 06013668 T PL06013668 T PL 06013668T PL 1873166 T3 PL1873166 T3 PL 1873166T3
Authority
PL
Poland
Prior art keywords
dimers
sgp
improved
dimer
molecules
Prior art date
Application number
PL06013668T
Other languages
English (en)
Inventor
Georg Wätzig
Dirk Seegert
Original Assignee
Conaris Res Institute Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conaris Res Institute Ag filed Critical Conaris Res Institute Ag
Publication of PL1873166T3 publication Critical patent/PL1873166T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL06013668T 2006-06-30 2006-06-30 Ulepszone dimery sgp 130Fc PL1873166T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06013668A EP1873166B1 (en) 2006-06-30 2006-06-30 Improved sgp 130Fc dimers

Publications (1)

Publication Number Publication Date
PL1873166T3 true PL1873166T3 (pl) 2011-03-31

Family

ID=37654867

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06013668T PL1873166T3 (pl) 2006-06-30 2006-06-30 Ulepszone dimery sgp 130Fc

Country Status (21)

Country Link
US (3) US8895012B2 (pl)
EP (1) EP1873166B1 (pl)
JP (1) JP5417171B2 (pl)
KR (1) KR101474817B1 (pl)
CN (1) CN101484472B (pl)
AT (1) ATE480568T1 (pl)
AU (1) AU2007263939B2 (pl)
BR (1) BRPI0713063B8 (pl)
CA (1) CA2656440C (pl)
CY (1) CY1110973T1 (pl)
DE (1) DE602006016765D1 (pl)
DK (1) DK1873166T3 (pl)
EA (1) EA015620B1 (pl)
ES (1) ES2352561T3 (pl)
HR (1) HRP20100663T1 (pl)
PL (1) PL1873166T3 (pl)
PT (1) PT1873166E (pl)
RS (1) RS51544B (pl)
SI (1) SI1873166T1 (pl)
UA (1) UA95636C2 (pl)
WO (1) WO2008000516A2 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006016765D1 (de) 2006-06-30 2010-10-21 Conaris Res Inst Ag Verbesserte sgp 130Fc Dimere
EP2388266B1 (en) 2007-05-11 2014-04-23 Altor BioScience Corporation Fusion molecules and IL-15 variants
EP2050759A1 (en) * 2007-10-19 2009-04-22 CONARIS research institute AG Soluble gp 130 muteins with improved binding activity
JP6251570B2 (ja) * 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
KR101776542B1 (ko) * 2013-09-20 2017-09-19 인텔 코포레이션 Ap 위치 조회
CA2953816C (en) 2014-06-30 2022-03-15 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
KR20240131465A (ko) * 2014-12-01 2024-08-30 훼링 비.브이. 선택적 il-6-트랜스-신호전달 억제제 조성물
EP3226888B1 (en) * 2014-12-01 2021-04-21 Ferring B.V. Administration of a selective il-6-trans-signalling inhibitor
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
WO2017194592A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of storing a separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
JP7122974B2 (ja) 2016-05-11 2022-08-22 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 変異免疫グロブリン結合ポリペプチド
EP3455241B1 (en) 2016-05-11 2022-02-23 Cytiva BioProcess R&D AB Method of cleaning and/or sanitizing a separation matrix
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
MX2019004681A (es) 2016-10-21 2019-10-07 Altor Bioscience Corp Moleculas basadas en il-15 multimericas.
CN108593912A (zh) * 2018-04-09 2018-09-28 北京大学深圳研究生院 一种可溶性cd38浓度的检测方法
CN108318689A (zh) * 2018-04-09 2018-07-24 北京大学深圳研究生院 一种多发性骨髓瘤的诊断方法
WO2020006469A1 (en) * 2018-06-29 2020-01-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating and reducing traumatic brain injury-associated impairments using sgp130
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
MX2022015517A (es) 2020-06-10 2023-01-16 Ferring Bv Compuesto farmaceutico para el tratamiento de la enfermedad cardiovascular aterosclerotica.
WO2022139580A1 (en) 2020-12-22 2022-06-30 Ferring B.V. Blood gene expression biomarkers to predict response in patients with inflammatory bowel diseases
CN114681592A (zh) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 包含可溶性gp130二聚体的制剂和使用方法
US20240359144A1 (en) * 2021-09-01 2024-10-31 Telix Pharmaceuticals (Innovations) Pty Ltd Aggregate separation method
WO2024011946A1 (en) * 2022-07-12 2024-01-18 I-Mab Biopharma (Hangzhou) Co., Ltd Polypeptide dimers for the treatment of systemic sclerosis
EP4570816A1 (en) 2023-12-14 2025-06-18 Consejo Superior De Investigaciones Científicas - CSIC Soluble gp130fc (sgp130fc) for use in the treatment of sars-cov-2

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
BR9908226A (pt) * 1998-02-25 2000-10-24 Lexigen Pharm Corp Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
DE19941897B4 (de) 1999-09-02 2006-06-14 GSF - Forschungszentrum für Umwelt und Gesundheit GmbH IL-6 Rezeptor-Protein, Beta-Kette (gp130) des IL-6 Rezeptor-Proteins, für diese Proteine kodierende DNA, davon abgeleitete RNA, Peptid mit den Aminosäuren 771-811 dieser Beta-Kette oder Teilen davon und deren Verwendungen
JP5179689B2 (ja) * 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
DE60037648T2 (de) * 2000-04-21 2010-06-17 Conaris Research Institute Ag Fusionsproteine, die zwei lösliche gp130 Moleküle enthalten
KR20030097876A (ko) 2001-05-21 2003-12-31 넥타르 테라퓨틱스 화학적으로 개질된 인슐린의 폐 투여
WO2003008454A2 (en) * 2001-07-18 2003-01-30 Merck Patent Gmbh Glycoprotein vi fusion proteins
WO2003024389A2 (en) * 2001-07-30 2003-03-27 Immunex Corporation T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using
ATE385806T1 (de) * 2003-06-12 2008-03-15 Lilly Co Eli Fusionsproteine
EP1491554A1 (en) 2003-06-23 2004-12-29 CONARIS research institute AG PEGylated soluble gp130-dimers useful as a medicament
EP1699821B1 (en) * 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
ES2309427T3 (es) 2004-08-27 2008-12-16 Conaris Research Institute Ag Secuencias de nucleotidos optimizidas que codifican para sgp130.
EP1801121A1 (en) 2005-12-23 2007-06-27 CONARIS research institute AG Soluble gp130 molecule variants useful as a medicament
DE602006016765D1 (de) 2006-06-30 2010-10-21 Conaris Res Inst Ag Verbesserte sgp 130Fc Dimere

Also Published As

Publication number Publication date
CY1110973T1 (el) 2015-06-11
US9573989B2 (en) 2017-02-21
KR101474817B1 (ko) 2014-12-22
WO2008000516B1 (en) 2008-05-08
US20150361157A1 (en) 2015-12-17
EP1873166B1 (en) 2010-09-08
CN101484472B (zh) 2013-07-24
EA015620B1 (ru) 2011-10-31
WO2008000516A2 (en) 2008-01-03
WO2008000516A3 (en) 2008-03-27
KR20090037898A (ko) 2009-04-16
AU2007263939A1 (en) 2008-01-03
US9034817B2 (en) 2015-05-19
HRP20100663T1 (hr) 2011-01-31
AU2007263939B2 (en) 2011-11-24
BRPI0713063A2 (pt) 2012-04-17
SI1873166T1 (sl) 2011-01-31
DK1873166T3 (da) 2010-12-20
JP2009540843A (ja) 2009-11-26
US20100028367A1 (en) 2010-02-04
US20140178378A1 (en) 2014-06-26
ATE480568T1 (de) 2010-09-15
CN101484472A (zh) 2009-07-15
ES2352561T3 (es) 2011-02-21
EA200802396A1 (ru) 2009-06-30
JP5417171B2 (ja) 2014-02-12
UA95636C2 (en) 2011-08-25
BRPI0713063B1 (pt) 2019-10-08
US8895012B2 (en) 2014-11-25
DE602006016765D1 (de) 2010-10-21
BRPI0713063B8 (pt) 2021-05-25
EP1873166A1 (en) 2008-01-02
PT1873166E (pt) 2010-12-09
CA2656440A1 (en) 2008-01-03
CA2656440C (en) 2018-10-02
RS51544B (sr) 2011-06-30

Similar Documents

Publication Publication Date Title
SI1873166T1 (sl) IZBOLJĹ ANI sgp 130Fc DIMERJI
NZ592509A (en) HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same
DK1347730T3 (da) Rekombinante anti-CD30-antistoffer og anvendelser deraf
BRPI0406800B8 (pt) "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso
ATE294817T1 (de) Concatamere immunadhäsion
CA2648109A1 (en) Combination of an anti-ed-b fibronectin domain antibody-il-2 fusion protein and gemcitabine
WO2005001038A3 (en) Recombinant anti-cd30 antibodies and uses thereof
BRPI0511421A (pt) composições cosmética e farmacêutica para tratar materiais contendo queratina, uso de composições cosméticas, molécula efetora que liga queratina, uso da mesma, e, processo
UY31123A1 (es) Proteinas de fusion natriureticas
EA200700391A1 (ru) Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1
WO2006001023A3 (en) Chimeric proteins and uses thereof
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
BRPI0720879A2 (pt) microvesícula derivada de fermento carreador de fator de tecido (tf), composição e composição farmacêutica que a compreende, processos para a sua manufatura, proteína lipida de fator de tecido (tf) modificado, polinucleotídeo, vetor, célula hospedeira e anticorpo.
EA200601738A1 (ru) Модифицированные белки буганины, цитотоксины и способы их применения
ATE551048T1 (de) Proteinhydrolysate enthaltende kosmetische zusammensetzungen
CY1109631T1 (el) Χρησιμοποιηση πεπτιδιων, τα οποια εχουν παραχθει απο την αα- ή ββ-αλυσιδα του ανθρωπινου ινωδογονου, για τη θεραπεια σοκ
SI1511770T1 (sl) Glikoprotein VI-Fc fuzijski protein za zdravljenje vaskularnih bolezni
PL2010563T3 (pl) Sekwencja syntetycznego MECP2 do białkowej terapii substytucyjnej
WO2002048180A3 (de) Peptide und/oder proteine sowie verwendung desselben zur herstellung eines therapeutischen und/oder präventiven arzneimittels
DE602006017667D1 (de) Cysteinhaltiges peptid-tag zur stellenspezifischen konjugation von proteinen
WO2008003707A3 (en) Minimized small peptides with high affinity for factor viii and factor viii-like proteins
WO2012078761A3 (en) Dimeric molecular complexes with free cysteine residues and conjugates thereof
WO2006083964A3 (en) Modified fusion molecules for treatment of allergic disease
WO2008062158A3 (en) Polypeptide monomers and dimers containing mutated ilt
WO2007010285A3 (en) Crystal structure of human soluble adenylate cyclase